Early results from a UCL and UCLH-led clinical trial suggest that a type of CAR T-cell therapy - developed by Autolus Therapeutics, a UCL spinout - could offer a new treatment approach for people with severe, treatment-resistant lupus. The findings, presented at the EULAR European Congress of Rheumatology, come from the ongoing Phase I CARLYSLE study, which is evaluating obecabtagene autoleucel (obe-cel) in patients with severe refractory systemic lupus erythematosus (SLE). The early data